Atypical Cell Cycle Regulation Promotes Mammary Stem Cell Expansion and Therapeutic Resistance
Bre‐Anne FifieldiD, John VusichiD, Erika Haberfellner, Eran R. AndrechekiD, Lisa Ann PorteriD
Abstract
BackgroundThe cell cycle of mammary stem cells must be tightly regulated to ensure normal homeostasis of the mammary gland to prevent abnormal proliferation and susceptibility to tumorigenesis. The atypical cell cycle regulator, Spy1 can override cell cycle checkpoints, including those activated by the tumour suppressor p53 which mediates mammary stem cell homeostasis. Spy1 has also been shown to promote expansion of select stem cell populations in other developmental systems. Spy1 protein is elevated during proliferative stages of mammary gland development, is found at higher levels in human breast cancers, and promotes susceptibility to mammary tumourigenesis when combined with loss of p53. We hypothesized that Spy1 cooperates with loss of p53 to increase susceptibility to tumour initiation due to changes in susceptible mammary stem cell populations during development and drives the formation of more aggressive stem like tumours. MethodsUsing a transgenic mouse model driving expression of Spy1 within the mammary gland, mammary development and stemness were assessed. These mice were intercrossed with p53 null mice to study the tumourigenic properties of Spy1 driven p53 null tumours, as well as global changes in signaling via RNA sequencing analysis. ResultsWe show that elevated levels of Spy1 leads to expansion of mammary stem cells, even in the presence of p53, and an increase in mammary tumour formation. Spy1-driven tumours have an increased cancer stem cell population, decreased checkpoint signaling, and demonstrate an increase in therapy resistance. Loss of Spy1 decreases tumor onset and reduces the cancer stem cell population. ConclusionsThis data demonstrates the potential of Spy1 to expand mammary stem cell populations and contribute to the initiation and progression of aggressive, drug resistant breast cancers with increased cancer stem cell populations.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- FWCI
- 0.34
- Field percentile
- top 45%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The Atypical Cyclin-Like Protein Spy1 Overrides p53-Mediated Tumour Suppression and Promotes Susceptibility to Breast Tumorigenesis
B.-A. Fifield, I. Qemo, … L. A. Porter·Breast Cancer ResearchPeer-reviewed·Dec 11, 2019
- THE STABILIZATAION OF C-MYC BY THE NOVEL CELL CYCLE REGULATOR, SPY1, DECREASES EFFICACY OF BREAST CANCER TREATMENTS
R.-M. Ferraiuolo, B.-A. Fifield, … L. A. Porter·bioRxiv·Mar 11, 2022
- The Cyclin-Like Protein Spy1 Mediates Tumourigenic Potential of Triple Negative Breast Cancer
Bre‐Anne Fifield, Claudia Pecoraro, … Lisa Ann Porter·bioRxiv·Mar 11, 2024
- MYC-driven epigenetic reprogramming favors the onset of tumorigensis by inducing a stem cell-like state
V. Poli, L. Fagnocchi, … A. Zippo·bioRxiv·Dec 29, 2017
- APRIL and BAFF increase breast cancer cell stemness
V. Pelekanou, G. Notas, … M. Kampa·bioRxiv·Oct 11, 2017
- Acquisition of cancer stem cell properties during EMT requires cell division
P. den Hollander, S. V. Vasaikar, … S. A. Mani·bioRxiv·Jul 1, 2021